BioStem (BSEM) CFO Brandon Poe Exercises 10,634 Derivative Shares

What Happened
Brandon Poe, Chief Financial Officer of BioStem Technologies (BSEM), reported the exercise/conversion of 10,634 derivative units on August 11, 2026. The Form 4 shows 10,634 shares acquired and a simultaneous disposition of 10,634 derivative units, both at $0.00 (no cash consideration or proceeds reported).

Key Details

• Transaction date: 2026-08-11 (reported on Form 4 filed 2026-08-20).
• Reported transactions: M (exercise/conversion of derivative) — 10,634 shares acquired @ $0.00; 10,634 shares disposed @ $0.00 (derivative).
• Shares owned after transaction: Not specified in the provided filing details.
• Relevant footnotes: F3 notes each restricted stock unit (RSU) equals one common share; F5 states 33% of these RSUs vested on August 11, 2026 and that the vesting was not timely reported due to an administrative error. Other footnotes (F1–F2, F4–F6) describe standard vesting schedules for options/RSUs.
• Timeliness: Filing was late relative to the two-business-day Form 4 reporting requirement; footnote F5 acknowledges an administrative reporting delay.

Context
The filing records a conversion/exercise event rather than an open-market purchase or sale by the insider. Because both acquisition and a derivative disposition are shown at $0.00 and no cash proceeds are reported, this appears to reflect the vesting/conversion/settlement of equity awards (RSUs/options) rather than a market sale. The late filing was attributed to an administrative error per the issuer's footnote.